AI generated
Aug 11, 2026, 13:34
Brett Hoover: Plaque Burden May Be Key to Predicting MACE Risk
Brett Hoover, Senior Director of Global Project Management, Medical Imaging and Specialty Solutions at Clario, shared a post on LinkedIn:
“New CCTA Study Suggests that Current Plaque is the Key Biomarker for Assessing major adverse cardiovascular events (MACE) risk.
Emerging research demonstrates that those with total plaque volume more than 750 mm3 have an 18.6 percent risk of MACE at four years in comparison to a 1.4 percent MACE risk for those with no plaque.”
Stay updated with Hemostasis Today.
-
Nov 17, 2026, 01:27X. Long Zheng: Optimizing Treatment in Immune TTP
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C